Super Copy of Great Power Technology

Two months after the zombie virus outbreak, the Chinese medical team aiding Mexico published a paper in the professional journal *Cell*, titled "On the Possibility of Gene Enhancement Therapy for the Prevention and Treatment of Zombie Viruses." This was the first time a human research team had proposed a systematic treatment and prevention plan since the outbreak of the zombie virus. Upon publication, it immediately caused a sensation in the global medical community, rekindling the hope for humanity's fight against the zombie virus.

The origins of gene enhancement therapy can be traced back to the Strong Root No. 4 gene enhancement drug released last year by Ruida Pharmaceuticals. At the time of its release, to explain the drug's mechanism of action, Ruida Pharmaceuticals' research team published over a dozen papers in relevant journals, comprehensively discussing methods for treating various common and chronic diseases by enhancing the body's immune system through gene modification—collectively known as gene enhancement therapy. Strong Root No. 4 is the first drug developed based on gene enhancement therapy.

Upon arriving in Mexico, the Chinese medical team discovered that their medical personnel appeared to possess resistance to the zombie virus. Medical aid teams from surrounding countries, even with the most comprehensive protective measures, saw one to several medical staff members contract the zombie virus while treating patients. The Chinese medical team, the largest in number and treating the most patients, had no members infected with the zombie virus.

As time went on, medical aid teams from various countries withdrew and returned home due to the increasing number of infected medical staff who could no longer be treated. However, the Chinese medical aid team remained steadfast on the front lines of treating the zombie virus, never leaving, and none of its medical staff were infected. The reason for this is likely that all members of the Chinese medical team received a unified injection of the Strong Root No. 4 gene-enhancing drug before departing for Mexico. This was originally a benefit offered to all medical staff participating in the Chinese medical aid team to Mexico, but unexpectedly, it became an impenetrable bulwark against the zombie virus.

A treatment method has been found, and there's only one medication available: the Strong Root No. 4 gene-enhancing agent produced by Ruida Pharmaceuticals. Clinical trials have shown that Strong Root No. 4 is effective in treating early to mid-stage zombie virus infections; the effects are significant and immediate after injection, with patients typically recovering and being discharged within two to three days. However, for patients in the later stages of infection, those who have already turned into zombies, the Strong Root No. 4 agent has no effect. This is perhaps because in late-stage infections, consciousness dissipates, and the brain is nearing death, rendering even the most potent drug powerless.

In addition, there's more bad news: Strong Foundation IV is only effective for Chinese people and most people of East Asian descent. Those of Chinese descent or Asian immigrant descent have generally received effective treatment. However, the drug has no effect on Caucasians or Black people, and naturally, it cannot treat those infected with the zombie virus in these two skin colors. This isn't discriminatory treatment by the Chinese medical team; rather, Strong Foundation IV is a gene-enhancing drug specifically developed for the Chinese physique, so its ineffectiveness on other ethnicities is understandable.

In response to this situation, rumors spread like wildfire internationally, ranging from genocide and human extermination programs to genetic weapons—nothing was kind, and the comments were extremely harsh. Under pressure from public opinion, Ruida Pharmaceuticals held a press conference, emphasizing the working principle, development process, and timeline of the Strong Foundation No. 4, thus proving that the Strong Foundation No. 4 project had been initiated several years prior and had absolutely no connection to the current zombie virus outbreak. The fact that the Strong Foundation No. 4 could treat zombie virus patients was purely coincidental.

At the press conference, a white reporter asked whether a gene-enhancing drug effective against both white and black people was under development and when it would be successfully developed. The spokesperson paused briefly before replying, "Since the outbreak of the zombie virus, our research team at Ruida Pharmaceuticals immediately established a special task force to conduct gene sequencing and pathogenic mechanism analysis of this virus, investing significant manpower and resources in developing drugs and vaccines to treat it. After discovering that Strong Gene No. 4 was effective against the zombie virus but ineffective against white and black patients, the researchers immediately shifted their focus to developing a gene-enhancing drug effective against both white and black people. However, as is well known, the development process for gene-enhancing drugs is extremely lengthy. Even after successful development, the drug must undergo two to three years of clinical trials before it can be marketed. The exact timeline for when the gene-enhancing drug will be successfully developed and mass-produced is currently unpredictable."

Just days after the press conference, China launched a nationwide enhancement program, encouraging all citizens to receive free injections of the "Strong Foundation IV" vaccine. Against the backdrop of a global zombie virus outbreak, this program was undoubtedly a benevolent initiative that benefited the country and its people, comprehensively strengthening the physical fitness of the entire population and effectively combating the zombie virus. Upon its release, it received overwhelming support from the entire nation.

To implement the plan, the national health department spent a huge sum of money to purchase a massive quantity of Qiangji No. 4 drug from Ruida Pharmaceutical Company. As a responsible entrepreneur, Qiao Ruida certainly wouldn't profit from a national crisis. He calculated the costs and proactively lowered the price, reducing the purchase price of one dose of Qiangji No. 4 to one hundred yuan. This price barely covered the production and labor costs; producing more would not generate much profit.

Once some of the drugs were procured, the nationwide enhancement plan was immediately launched. Those first to receive the injections were not officials or the wealthy, but rather medical personnel, staff working in customs, airports, and ports, and the general public living in border areas. They were on the front lines of the fight against the zombie virus and faced the greatest risk of infection, so it was perfectly understandable that they were the first to receive the Enhanced Foundation IV.

With the large-scale implementation of the National Enhancing Drug Program, the demand for the Strong Foundation IV drug is enormous. Even though Ruida Pharmaceutical Company suspended the production of other injectable drugs, adjusted its production lines, and had employees working in three shifts to keep the equipment running, its daily production capacity for the Strong Foundation IV drug could only reach about two thousand doses. This production capacity is already quite staggering for a pharmaceutical company and for a single drug, but it is still not fast enough for China's more than one billion people waiting for injections.

In order to complete the nationwide enhancement plan as soon as possible, establish an immune defense against the zombie virus, and escape the economic quagmire, the production capacity of the Strong Foundation No. 4 drug should naturally be as high as possible. (End of this chapter)